Lexaria Bioscience announced that approval has been received from an independent review board, for human pilot study #3, investigating a DehydraTECH-processed version of the dual action GLP-1 + GIP tirzepatide in an oral dose format. Subject recruitment will begin shortly and the Company will announce as soon as the first dosing has begun, currently expected in late October. Lexaria anticipates the final doses in the study to be administered in late November. The Study will be conducted in up to 10 healthy volunteers and will study a single injected dose of Zepbound monitored over a 7-day duration, compared to 7 consecutive days of daily oral dosing of DehydraTECH-processed Zepbound.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience Appoints New CEO for Growth Era
- Lexaria Bioscience Ushers in New Leadership and Focus
- Lexaria Bioscience CEO Chris Bunka steps down, Richard Christopher to succeed
- Lexaria Bioscience Advances Drug Delivery with PharmaCO Partnership
- Lexaria Bioscience enters material transfer agreement for DehydraTECH research